TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20871453

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) with embolization
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stereotactic radiosurgery (SRS) alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cavernous carotid fistulas
Number of subjects: 40
Study: 17023874

Group type: EXPERIMENTAL
Intervention: Physical activity (increased levels)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Physical activity (increased levels) in non-HT users
Number of subjects: 485

Group type: COMPARATOR
Intervention: Hormone therapy (HT) users
Number of subjects: 485

Group type: COMPARATOR
Intervention: Non-hormone therapy (non-HT) users
Number of subjects: 485
Study: 15863490

Group type: EXPERIMENTAL
Intervention: Sustained lung inflation (5 seconds)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional lung inflation (2 seconds)
Number of subjects: 52
Study: 11980938

Group type: EXPERIMENTAL
Intervention: 10% povidone‐iodine
Number of subjects: 12692

Group type: EXPERIMENTAL
Intervention: Tincture of iodine
Number of subjects: 12692

Group type: EXPERIMENTAL
Intervention: 70% isopropyl alcohol
Number of subjects: 12692

Group type: EXPERIMENTAL
Intervention: Povidone‐iodine with 70% ethyl alcohol (Persist)
Number of subjects: 12692

Group type: COMPARATOR
Intervention: Previous 12-month period (control)
Number of subjects: 12692
Study: 10210789

Group type: EXPERIMENTAL
Intervention: Continuous monotherapy
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Intermittent therapy
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both treatment methods
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Elderly patients
Number of subjects: 37
Study: 8675066

Group type: EXPERIMENTAL
Intervention: EPH gestosis group
Number of subjects: 70

Group type: COMPARATOR
Intervention: Normal pregnant women group
Number of subjects: 70
Study: 1983499

Group type: EXPERIMENTAL
Intervention: Symptomatic therapy with clomethiazol and haloperidol (group 1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Continuous ethanol infusions (2‐4 g/h) postoperatively as prophylaxis for WS (group 2)
Number of subjects: 50
Study: 7073790

Group type: EXPERIMENTAL
Intervention: Colestipol 0.125 g/kg body weight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colestipol 0.25 g/kg body weight
Number of subjects: 0
Study: 31615336

Group type: EXPERIMENTAL
Intervention: Traditional TA training as described by Ericsson and Simon
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Task-specific TA training
Number of subjects: 20
Study: 31311018

Group type: EXPERIMENTAL
Intervention: Intermittent infusion hemodiafiltration (I-HDF)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Hemodialysis (HD)
Number of subjects: 70
Study: 29075917

Group type: EXPERIMENTAL
Intervention: Observational treatment strategy
Number of subjects: 528

Group type: COMPARATOR
Intervention: Antibiotic treatment strategy
Number of subjects: 528
Study: 25704072

Group type: EXPERIMENTAL
Intervention: Allergen EPIT (n = 48)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo EPIT (n = 50)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Allergen EPIT
Number of subjects: 98
Study: 25534747

Group type: EXPERIMENTAL
Intervention: Triflusal 900 mg loading dose on Day 1, followed by 600 mg/day from Day 2 to 9
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 34
Study: 21134450

Group type: EXPERIMENTAL
Intervention: Tdap (Boostrix® GlaxoSmithKline) and MCV4 (Menactra®, Sanofi‐Pasteur) co-administered
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Tdap (Boostrix® GlaxoSmithKline) and MCV4 (Menactra®, Sanofi‐Pasteur) administered sequentially one month apart
Number of subjects: 1341
Study: 19939445

Group type: EXPERIMENTAL
Intervention: Home-based care
Number of subjects: 1453

Group type: COMPARATOR
Intervention: Facility-based care
Number of subjects: 1453
Study: 19758646

Group type: EXPERIMENTAL
Intervention: 20 gm soy protein containing 160 mg total isoflavones
Number of subjects: 33

Group type: COMPARATOR
Intervention: 20 gm whole milk protein (placebo)
Number of subjects: 33
Study: 16382590

Group type: EXPERIMENTAL
Intervention: LED curing light (fast curing mode)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: LED curing light (pulse curing mode)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: LED curing light (stepped curing mode)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Visible curing light
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vickers hardness test
Number of subjects: 40
Study: 11978848

Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dizygotic co-twins discordant for schizophrenia
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Monozygotic co-twins of schizophrenia probands
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy control twins
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lateral and third ventricle enlargements
Number of subjects: 40
Study: 9397059

Group type: EXPERIMENTAL
Intervention: ThinPrep Pap test
Number of subjects: 35560
Study: 7955966

Group type: EXPERIMENTAL
Intervention: HRCT scanning in asbestos-exposed workers
Number of subjects: 70
Study: 3655274

Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Duration-Intensity-Behavior Scale (DIBS)
Number of subjects: 32
Study: 12510944

Group type: EXPERIMENTAL
Intervention: Ibuprofen (up to 1.2 g daily)
Number of subjects: 2815

Group type: EXPERIMENTAL
Intervention: Aspirin (up to 3 g daily)
Number of subjects: 2815

Group type: EXPERIMENTAL
Intervention: Paracetamol (up to 3 g daily)
Number of subjects: 2815

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 2815

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 2815
Study: 29254399

Group type: EXPERIMENTAL
Intervention: PSA screening
Number of subjects: 9950

Group type: COMPARATOR
Intervention: Control
Number of subjects: 9950

Group type: EXPERIMENTAL
Intervention: PSA screening (age 55-59)
Number of subjects: 9950

Group type: EXPERIMENTAL
Intervention: PSA screening (low education)
Number of subjects: 9950
Study: 26892284

Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 315

Group type: COMPARATOR
Intervention: Control
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Post‐treatment infarct volume
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Delta National Institute of Health Stroke Scale
Number of subjects: 315
Study: 23848177

Group type: EXPERIMENTAL
Intervention: Navarakizhi
Number of subjects: 18

Group type: COMPARATOR
Intervention: Pinda sweda
Number of subjects: 18
Study: 22339556

Group type: EXPERIMENTAL
Intervention: Sphenopalatine artery ligation with nerve resection (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Functional endoscopic surgery without sphenopalatine artery ligation (group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 60
Study: 20659517

Group type: EXPERIMENTAL
Intervention: 15 microg hemagglutinin antigen
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 30 microg hemagglutinin antigen
Number of subjects: 107
Study: 18520587

Group type: EXPERIMENTAL
Intervention: Non-echo-planar diffusion-weighted MRI
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 32
Study: 15824943

Group type: EXPERIMENTAL
Intervention: Newly designed antireflux stent
Number of subjects: 36

Group type: COMPARATOR
Intervention: Dostent
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard open stent
Number of subjects: 36
Study: 12439773

Group type: EXPERIMENTAL
Intervention: 9-month jumping intervention (trainees, N = 50)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (controls, N = 49)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Proximal femur BMC accrual (trainees, N = 50)
Number of subjects: 99
Study: 10338219

Group type: EXPERIMENTAL
Intervention: rhGH (Genotropin; Pharmacia Ltd, Uppsala, Sweden) 0.3 IU/kg/d for 6 days before and after surgery
Number of subjects: 33

Group type: COMPARATOR
Intervention: rhGH (Genotropin; Pharmacia Ltd, Uppsala, Sweden) 0.3 IU/kg/d for 6 days after surgery
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo for 6 days before and after surgery
Number of subjects: 33
Study: 7796057

Group type: EXPERIMENTAL
Intervention: 0.17-0.34- or 0.51-M sucrose solution (2 ml)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Water (2 ml)
Number of subjects: 72
Study: 2019145

Group type: EXPERIMENTAL
Intervention: Right ventricular port cardiac output measurements
Number of subjects: 47

Group type: COMPARATOR
Intervention: Central venous port cardiac output measurements
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Right ventricular port cardiac output measurements in catheters located in the right ventricle
Number of subjects: 47
Study: 6963074

Group type: EXPERIMENTAL
Intervention: Extraamniotic PGF2 alpha
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intravenous PGE2
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intravenous sulprostone (2 schedules)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intramuscular sulprostone (2 schedules)
Number of subjects: 100
Study: 30933354

Group type: EXPERIMENTAL
Intervention: First-line platinum-based chemotherapy (carboplatin in combination with nab-paclitaxel or solvent-based paclitaxel)
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Quartile 1 (Q1) with >0% to 25% tumor reduction
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Quartile 2 (Q2) with >25% to 50% tumor reduction
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Quartile 3 (Q3) with >50% to 75% tumor reduction
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Quartile 4 (Q4) with >75% tumor reduction
Number of subjects: 959

Group type: COMPARATOR
Intervention: No tumor reduction (NTR)
Number of subjects: 959
Study: 27742412

Group type: EXPERIMENTAL
Intervention: Headache
Number of subjects: 0

Group type: COMPARATOR
Intervention: No headache
Number of subjects: 0
Study: 28053292

Group type: EXPERIMENTAL
Intervention: Polyphenon E® (PolyE®) containing 200 mg EGCG administered with food, BID
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 25056277

Group type: EXPERIMENTAL
Intervention: 11.25 mg of 0.75% intrathecal hyperbaric bupivacaine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 15.0 mg of 0.75% intrathecal hyperbaric bupivacaine
Number of subjects: 50
Study: 22059803

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (N = 72)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Orlistat plus low-fat diet (N = 74)
Number of subjects: 146
Study: 19856319

Group type: EXPERIMENTAL
Intervention: Topical capsaicin
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Avocado-soybean unsaponifiables
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Chinese herbal mixture SKI306X
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Devil's claw
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Powder from rose hip and seed
Number of subjects: 35

Group type: COMPARATOR
Intervention: Willow bark extract
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Phytodolor NR
Number of subjects: 35
Study: 17995656

Group type: EXPERIMENTAL
Intervention: Indirectly puffed snacks produced with 30%, 40%, 50% peanut flour at various screw speeds and feed rates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Product extruded with 50% peanut flour at screw speed of 400 rpm and feed rate of 6 kg/h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predicted regression models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimum region identified for consumer attributes
Number of subjects: 0
Study: 16377601

Group type: COMPARATOR
Intervention: Single Untailored (SU) group - one untailored set of materials
Number of subjects: 3402

Group type: EXPERIMENTAL
Intervention: Multiple Tailored (MT) group - four tailored materials
Number of subjects: 3402

Group type: EXPERIMENTAL
Intervention: Multiple Retailored (MRT) group - four tailored materials with retailoring
Number of subjects: 3402

Group type: EXPERIMENTAL
Intervention: Single Tailored (ST) group - one tailored booklet
Number of subjects: 3402

Group type: EXPERIMENTAL
Intervention: Multiple Tailored (MT) group
Number of subjects: 3402
Study: 11533291

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation and resistance training
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no supplementation or training)
Number of subjects: 98
Study: 9604192

Group type: EXPERIMENTAL
Intervention: Bandaging (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bracing (group B)
Number of subjects: 40
Study: 7790748

Group type: EXPERIMENTAL
Intervention: Stretch ePTFE (Gore‐Tex) prosthesis
Number of subjects: 379

Group type: COMPARATOR
Intervention: Dacron (Unigraft, Braun‐Melsungen) grafts
Number of subjects: 379
Study: 3132054

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 31951273

Group type: EXPERIMENTAL
Intervention: Volar locking plate
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Percutaneous pinning
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: External fixation
Number of subjects: 166

Group type: COMPARATOR
Intervention: Nonoperative treatment (casts)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 166
Study: 30170305

Group type: EXPERIMENTAL
Intervention: GAA-creatine mixture (1 gram of GAA and 3 grams of creatine per day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Creatine alone (4 grams per day)
Number of subjects: 14
Study: 28527386

Group type: EXPERIMENTAL
Intervention: CMTall (children with CMT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: CMTND (no difficulty heel or toe walking)
Number of subjects: 60

Group type: COMPARATOR
Intervention: CMTDH (difficulty heel walking)
Number of subjects: 60

Group type: COMPARATOR
Intervention: CMTDTH (difficulty toe and heel walking)
Number of subjects: 60
Study: 26583657

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate glue (Histoacryl)
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Self-gripping mesh (Parietex ProGrip)
Number of subjects: 625

Group type: COMPARATOR
Intervention: Conventional nonabsorbable sutures (Prolene 2-0)
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 625
Study: 23548511

Group type: EXPERIMENTAL
Intervention: Defatted milk (0.5%)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Whole milk
Number of subjects: 165
Study: 21752292

Group type: EXPERIMENTAL
Intervention: Aerosolized mixed oil preparation (aloe, coconut, orange, peppermint, vitamin E)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aerosolized mixed oil preparation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Orange oil
Number of subjects: 12
Study: 19845550

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 146

Group type: COMPARATOR
Intervention: Propofol with alfentanil
Number of subjects: 146
Study: 16709210

Group type: EXPERIMENTAL
Intervention: 12-week scan policy
Number of subjects: 39572

Group type: COMPARATOR
Intervention: 18-week scan policy
Number of subjects: 39572
Study: 14706058

Group type: EXPERIMENTAL
Intervention: Bedtime diazoxide, 100 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 11034946

Group type: EXPERIMENTAL
Intervention: Cardiac troponin T >0.10 ng/mL
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Total homocysteine level greater than median
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Baseline glucose (1 mmol/L increase)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Baseline triglycerides (1 mmol/L increase)
Number of subjects: 102
Study: 8810610

Group type: EXPERIMENTAL
Intervention: TGF-beta release in BAL cell culture (n=12; 1,422 +/- 215 pg/ml; p < 0.004)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: TGF-beta release in BAL cell culture (n=21; 677 +/- 159 pg/ml)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: TGF-beta release in BAL cell culture (n=6; 762 +/- 419 pg/ml)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: TGF-beta release in BAL cell culture (n=5; 1,560 +/- 353 pg/ml)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: IL-10 release
Number of subjects: 46

Group type: COMPARATOR
Intervention: TGF-beta release in BAL cell culture (612 +/- 261.2 pg/ml)
Number of subjects: 46
Study: 1565532

Group type: EXPERIMENTAL
Intervention: Erythromycin estolate (EST) 40 mg/kg/day divided in 2 doses
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate (ETH) 60 mg/kg/day divided in 3 doses
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Erythromycin estolate (EST)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate (ETH)
Number of subjects: 190
Study: 3907818

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (retinyl palmitate)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Placebo (0 IU)
Number of subjects: 376
Study: 31857506

Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg/d
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 29035923

Group type: EXPERIMENTAL
Intervention: Desktop USB‐powered humidifier
Number of subjects: 44

Group type: COMPARATOR
Intervention: No humidifier (control)
Number of subjects: 44
Study: 25912176

Group type: EXPERIMENTAL
Intervention: 3-month exercise and behavioral weight loss intervention
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study: 24456026

Group type: EXPERIMENTAL
Intervention: Sirolimus with reduced-dose tacrolimus (loading dose: 15 mg, initial dose: 5 mg titrated to a trough of 4-11 ng/mL; reduced-dose tacrolimus trough: 3-7 ng/mL)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Sirolimus with reduced-dose tacrolimus
Number of subjects: 222

Group type: COMPARATOR
Intervention: Conventional-dose tacrolimus (trough: 7-15 ng/mL)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Conventional-dose tacrolimus
Number of subjects: 222
Study: 21843929

Group type: EXPERIMENTAL
Intervention: Testosterone + Resistance Training (TR)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Placebo + Resistance Training (PR)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Testosterone + No Training (T)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo + No Training (P)
Number of subjects: 40
Study: 19043140

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg/day)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg/day)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Rosuvastatin and Atorvastatin (comparison)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Rosuvastatin and Atorvastatin (absolute values)
Number of subjects: 135
Study: 17438403

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 20
Study: 15346302

Group type: COMPARATOR
Intervention: Healthy test subjects
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Patients with plain impingement
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Patients with tendinosis calcarea
Number of subjects: 100
Study: 12725580

Group type: COMPARATOR
Intervention: Ivy leaf extract cough drops
Number of subjects: 3

Group type: COMPARATOR
Intervention: Ivy leaf extract syrup
Number of subjects: 3

Group type: COMPARATOR
Intervention: Ivy leaf extract suppositories
Number of subjects: 3
Study: 10350027

Group type: EXPERIMENTAL
Intervention: Amisulpride 50 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Amisulpride 400 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Haloperidol 4 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 8736055

Group type: EXPERIMENTAL
Intervention: Morphine and scopolamine
Number of subjects: 53

Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 53
Study: 1915134

Group type: EXPERIMENTAL
Intervention: Scopolamine i.v. (20 mg)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Placebo i.v. and scopolamine transdermally (0.5 mg)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Saline i.v. and saline transdermally
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Transdermally applied scopolamine (0.5 mg)
Number of subjects: 235
Study: 7041931

Group type: EXPERIMENTAL
Intervention: Phentolamine 0.5 mg min‐1 infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 2414066

Group type: EXPERIMENTAL
Intervention: Standard formulation (buclizine 6.25 mg, codeine 8 mg, paracetamol 500 mg, with docusate sodium 10 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination without docusate (buclizine 6.25 mg, codeine 8 mg, paracetamol 500 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Paracetamol alone (500 mg)
Number of subjects: 10
Study: 31321651

Group type: EXPERIMENTAL
Intervention: Radiomics signature based on T2-weighted images (T2WIs) incorporating 17 selected radiomics features
Number of subjects: 119
Study: 30701912

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (BS)
Number of subjects: 0
Study: 27838646

Group type: EXPERIMENTAL
Intervention: Exenatide (17.4 μg over a 6-hour and 15-minute infusion)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 23594059

Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention at a primary health centre (PHCG)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Physiotherapy intervention at the patients' place of domicile (DG)
Number of subjects: 52
Study: 22409923

Group type: EXPERIMENTAL
Intervention: Kanli Granule (Chinese herbs group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Western medicine (control group)
Number of subjects: 80
Study: 20820124

Group type: EXPERIMENTAL
Intervention: Taegyo program for 4 weeks
Number of subjects: 52
Study: 17149753

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day
Number of subjects: 240

Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/day
Number of subjects: 240
Study: 16153925

Group type: EXPERIMENTAL
Intervention: MCRI On-X valve
Number of subjects: 52

Group type: COMPARATOR
Intervention: CarboMedics Top Hat valve
Number of subjects: 52